Evidence map›Paper›PMID 29666931›Full record

ReviewCurrent cardiology reports2018

Genome Editing and Induced Pluripotent Stem Cell Technologies for Personalized Study of Cardiovascular Diseases.

Young Wook Chun, Matthew D Durbin, Charles C Hong

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Current cardiology reports, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Young Wook ChunDepartments of Medicine - Division of Cardiovascular Medicine, Vanderbilt University School of Medicine, 2220 Pierce Avenue, PRB 383, Nashville, TN, 37232, USA.
Matthew D DurbinDepartment of Pediatrics - Division of Neonatal-Perinatal Medicine, Indiana University School of Medicine, Indianapolis, IN, 46202, USA.
Charles C HongDepartments of Medicine - Division of Cardiovascular Medicine, Vanderbilt University School of Medicine, 2220 Pierce Avenue, PRB 383, Nashville, TN, 37232, USA. charles.c.hong@vanderbilt.edu.

Funding

The Vanderbilt Institute for Clinical and Translational Research (VICTR)UL1TR000445 · NCATS · VANDERBILT UNIVERSITY MEDICAL CENTER · PI BERNARD, GORDON RAPHAEL · 2012 to 2016
$41.4M
Understanding and preventing HLA-associated drug reactionsP50GM115305 · NIGMS · VANDERBILT UNIVERSITY MEDICAL CENTER · PI PHILLIPS, ELIZABETH · 2015 to 2019
$13.0M
Regulation and Maintenance of Cardiac Muscle Sarcomere IntegrityR01HL095813 · NHLBI · VANDERBILT UNIVERSITY · PI HONG, CHARLES C · 2010 to 2014
$2.1M
Cardiac Induction by Small Molecule BMP InhibitorsR01HL104040 · NHLBI · VANDERBILT UNIVERSITY · PI HONG, CHARLES C · 2010 to 2014
$2.0M
Novel Approach to Enhance Myocardial Performance and Improve Heart Failure OutcomeR01HL135129 · NHLBI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI HONG, CHARLES C · 2018 to 2021
$1.6M
NCATS NIH HHS UL1 TR000445NHLBI NIH HHS R01 HL095813NHLBI NIH HHS R01 HL104040NHLBI NIH HHS R01 HL135129NIGMS NIH HHS P50 GM115305
6 · The paper itself

Abstract

purpose of reviewThe goal of this review is to highlight the potential of induced pluripotent stem cell (iPSC)-based modeling as a tool for studying human cardiovascular diseases. We present some of the current cardiovascular disease models utilizing genome editing and patient-derived iPSCs. RECENT

findingsThe incorporation of genome-editing and iPSC technologies provides an innovative research platform, providing novel insight into human cardiovascular disease at molecular, cellular, and functional level. In addition, genome editing in diseased iPSC lines holds potential for personalized regenerative therapies. The study of human cardiovascular disease has been revolutionized by cellular reprogramming and genome editing discoveries. These exceptional technologies provide an opportunity to generate human cell cardiovascular disease models and enable therapeutic strategy development in a dish. We anticipate these technologies to improve our understanding of cardiovascular disease pathophysiology leading to optimal treatment for heart diseases in the future.

Indexed as

Models, BiologicalPrecision MedicineCardiovascular DiseasesCell DifferentiationGene EditingHumansInduced Pluripotent Stem CellsCardiomyocytesCardiovascular diseaseGenome editingInduced pluripotent stem cellsPersonalized medicine

Identifiers

PMID29666931
PMCPMC6204334

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.